![]() |
Name |
Eremofortin J
|
Molecular Formula | C26H40O5 | |
IUPAC Name* |
(6-hydroxy-1,8a-dimethyl-7-prop-1-en-2-yl-2,3,4,6,7,8-hexahydro-1H-naphthalen-2-yl)3,9-dihydroxy-2-methyldeca-4,6-dienoate
|
|
SMILES |
C=C(C)C1CC2(C)C(=CC1O)CCC(OC(=O)C(C)C(O)C=CC=CCC(C)O)C2C
|
|
InChI |
InChI=1S/C26H40O5/c1-16(2)21-15-26(6)19(5)24(13-12-20(26)14-23(21)29)31-25(30)18(4)22(28)11-9-7-8-10-17(3)27/h7-9,11,14,17-19,21-24,27-29H,1,10,12-13,15H2,2-6H3/b8-7+,11-9+/t17-,18+,19+,21+,22+,23-,24-,26-/m1/s1
|
|
InChIKey |
QLOHOILEZBAWOV-XVNISSNUSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 432.6 | ALogp: | 4.1 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 31 | QED Weighted: | 0.294 |
Caco-2 Permeability: | -4.786 | MDCK Permeability: | 0.00001980 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.077 |
Human Intestinal Absorption (HIA): | 0.712 | 20% Bioavailability (F20%): | 0.008 |
30% Bioavailability (F30%): | 0.377 |
Blood-Brain-Barrier Penetration (BBB): | 0.776 | Plasma Protein Binding (PPB): | 74.46% |
Volume Distribution (VD): | 1.89 | Fu: | 15.34% |
CYP1A2-inhibitor: | 0.011 | CYP1A2-substrate: | 0.137 |
CYP2C19-inhibitor: | 0.016 | CYP2C19-substrate: | 0.912 |
CYP2C9-inhibitor: | 0.008 | CYP2C9-substrate: | 0.653 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.491 |
CYP3A4-inhibitor: | 0.464 | CYP3A4-substrate: | 0.693 |
Clearance (CL): | 10.222 | Half-life (T1/2): | 0.083 |
hERG Blockers: | 0.163 | Human Hepatotoxicity (H-HT): | 0.424 |
Drug-inuced Liver Injury (DILI): | 0.049 | AMES Toxicity: | 0.009 |
Rat Oral Acute Toxicity: | 0.208 | Maximum Recommended Daily Dose: | 0.948 |
Skin Sensitization: | 0.171 | Carcinogencity: | 0.76 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.008 |
Respiratory Toxicity: | 0.919 |